Human papillomavirus vaccine recombinant quadrivalent - Serum Institute of India

Drug Profile

Human papillomavirus vaccine recombinant quadrivalent - Serum Institute of India

Alternative Names: Human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine - Serum Institute of India; Human papillomavirus (types 6, 11, 16, 18) L1 VLP vaccine - Serum Institute of India; Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine - Serum Institute of India; Tetravalent HPV vaccine - Serum Institute of India

Latest Information Update: 09 Aug 2016

Price : $50

At a glance

  • Originator Serum Institute of India
  • Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Human papillomavirus infections

Most Recent Events

  • 09 Aug 2016 Preclinical trials in Human papillomavirus infections (Prevention) in India (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top